in which:

n is 1, 2 or 3;

A is chosen from —X₁C(O)OR₆, —X₁OP(O)(OR₆)₂, —X₁P(O)(OR₆)₂, —X₁S(O)₂OR₆, —X₁P(O)(R₆)OR₆ and 1H-tetrazol-5-yl; wherein X₁ is chosen from a bond and C_1-3alkylene; and each R₆ is independently chosen from hydrogen and C_1-6alkyl;

X is a bond or is chosen from C_1-4alkyelene, —X₁OX₂—, —X₁NR₇X₂—, —X₁C(O)NR₇X₂—, —X₁NR₇C(O)X₂—, —X₁S(O)X₂—, —X₁S(O)₂X₂—, —X₁SX₂— and C_2-9heteroarylene; wherein X₁ and X₂ are independently chosen from a bond and C_1-3alkylene; R₇ is chosen from hydrogen and C_1-6alkyl; and any heteroarylene of X is optionally substituted by a member of the group chosen from halo and C_1-6alkyl;

Y is C_6-10aryl, wherein any aryl of Y can be optionally substituted with 1 to 3 radicals chosen from halo, hydroxy, cyano, nitro, C_1-6alkyl, C_1-6alkoxy, halo-substituted C_1-6alkyl and halo-substituted C_1-6alkoxy;

R₁ is chosen from C_6-10aryl and C_2-9heteroaryl; wherein any aryl or heteroaryl of R₁ is substituted by a radical chosen from C_6-10arylC_0-4alkyl, C_2-9heteroarylC_0-4alkyl, C_3-8cycloalkylC_0-4alkyl, or C_3-8heterocycloalkylC_0-4alkyl; wherein any aryl, heteroaryl, cycloalkyl or heterocycloalkyl group of R₁ can be optionally substituted by one to five radicals chosen from halo, C_1-6alkyl, C_1-6alkoxy, halo-substituted-C_1-6alkyl and halo-substituted-C_1-6alkoxy; and any alkyl group of R₁ can optionally have a methylene replaced by an atom or group chosen from —S—, —S(O)—, —S(O)₂—, —NR₇— and —O—; wherein R₇ is chosen from hydrogen or C_1-6alkyl;

R₂, R₃, R₄ and R₅ are independently chosen from hydrogen, C_1-6alkyl, halo, hydroxy, C_1-6alkoxy, halo-substituted C_1-6alkyl and halo-substituted C_1-6alkoxy; and the pharmaceutically acceptable salts, hydrates, solvates, isomers and prodrugs thereof.